Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Doha Naga"'
Autor:
Doha Naga, Smaragda Dimitrakopoulou, Sonia Roberts, Elisabeth Husar, Susanne Mohr, Helen Booler, Eunice Musvasva
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-16 (2023)
Abstract In-vivo toxicity assessment is an important step prior to clinical development and is still the main source of data for overall risk assessment of a new molecular entity (NCE). All in-vivo studies are performed according to regulatory requir
Externí odkaz:
https://doaj.org/article/29caf756a49742ddb010ee163c88d7a3
Publikováno v:
Journal of Cheminformatics, Vol 14, Iss 1, Pp 1-19 (2022)
Abstract Unpredicted drug safety issues constitute the majority of failures in the pharmaceutical industry according to several studies. Some of these preclinical safety issues could be attributed to the non-selective binding of compounds to targets
Externí odkaz:
https://doaj.org/article/d4e4116dcb3e468a8a8dc68776a347cc
Autor:
Doha Naga, Smaragda Dimitrakopoulou, Sonia Roberts, Elisabeth Husar, Susanne Mohr, Helen Booler, Eunice Musvasva
In-vivo toxicity assessment is an important step prior to clinical development and is still the main source of data for overall risk assessment of a new molecular entity (NCE). All in-vivo studies are performed according to regulatory requirements an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aff8858ec323ce04a8a3997df28584a7
https://doi.org/10.1101/2022.08.06.503048
https://doi.org/10.1101/2022.08.06.503048
Publikováno v:
Molecular pharmaceutics. 19(7)
Minimizing in vitro and in vivo testing in early drug discovery with the use of physiologically based pharmacokinetic (PBPK) modeling and machine learning (ML) approaches has the potential to reduce discovery cycle times and animal experimentation. H
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3495d9c8121a6393b38d2bebb235f9f
https://pubmed.ncbi.nlm.nih.gov/35476457
https://pubmed.ncbi.nlm.nih.gov/35476457
Publikováno v:
Methods in molecular biology (Clifton, N.J.). 2425
The present contribution describes how in silico models and methods are applied at different stages of the drug discovery process in the pharmaceutical industry. A description of the most relevant computational methods and tools is given along with a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::53ba3cd8d0c20432a49f6ee0c24fea7f
https://pubmed.ncbi.nlm.nih.gov/35188649
https://pubmed.ncbi.nlm.nih.gov/35188649
Publikováno v:
Journal of Cheminformatics
Unpredicted drug safety issues constitute the majority of failures in the pharmaceutical industry according to several studies. Some of these preclinical safety issues could be attributed to the non-selective binding of compounds to targets other tha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c986e78ad16f5039a105caf11404f4c
https://phaidra.univie.ac.at/o:1673251
https://phaidra.univie.ac.at/o:1673251
Publikováno v:
Methods in Molecular Biology ISBN: 9781071619599
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3f1baf17e637617c34b2dbaa3233146c
https://doi.org/10.1007/978-1-0716-1960-5_24
https://doi.org/10.1007/978-1-0716-1960-5_24
Unpredicted drug safety issues constitute the majority of failures in the pharmaceutical industry according to several studies[1-3]. Some of these preclinical safety issues could be attributed to the non-selective binding of compounds to targets othe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::48fcc97e56b41ca40def6fce5901d5fc
https://doi.org/10.21203/rs.3.rs-957525/v1
https://doi.org/10.21203/rs.3.rs-957525/v1